JAJonathan P. Ariyaratnam

Jonathan P. Ariyaratnam

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jonathan P. Ariyaratnam has a total of 67 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Left Atrial Reservoir Strain To Identify Advanced Atrial Cardiomyopathy in Patients With Atrial Fibrillation

    by Mohamed Abbas, Jenelle Dziano, Jackson Howie, Suraya Hani Kamsani, John Fitzgerald, Shaun Evans, Mohanaraj Jayakumar, Adrian D. Elliott, Prashanthan Sanders, Jonathan P. Ariyaratnam

  • Open Access

    Non-linear associations between blood pressure and clinical outcomes in atrial fibrillation: a systematic review and dose-response meta-analysis

    by Elnaz Shahmohamadi, Alessandra Pina, Adrian D Elliott, Jonathan P Ariyaratnam, Melissa E Middeldorp, Prashanthan Sanders

    Aims: Hypertension carries the highest attributable risk for atrial fibrillation (AF) and strongly influences clinical outcomes such as stroke and death; however, the optimal blood pressure targets in individuals with AF remain poorly defined. We aimed to characterize the dose-response relationship between systolic blood pressure (SBP) and diastolic blood pressure (DBP) and ischaemic stroke, all-cause mortality, and intracranial haemorrhage. Methods and results: We systematically searched MEDLINE, Embase, and Scopus for studies reporting outcomes in AF stratified by SBP and DBP. A two-stage dose-response meta-analysis used restricted cubic splines to model non-linearity, with within-study correlation handled by the Greenland–Longnecker method. Twenty-three studies (17 cohorts; n = 476 750) were included. SBP demonstrated a U-shaped association with all-cause mortality, with the lowest risk at 134 mmHg (relative risks (RR) 0.92, 0.86–0.98 vs. 120 mmHg). DBP exhibited a J-shaped association, with the lowest risk at 83 mmHg (RR 0.99, 0.97–1.02). In contrast to mortality, the risks of ischaemic stroke, intracranial haemorrhage, and stroke or systemic embolism rose progressively with SBP, with a steepening gradient. At 140 vs. 120 mmHg, the RR was 1.51 for intracranial haemorrhage against 1.08 for ischaemic stroke, reaching 1.99 vs. 1.14 at 150 mmHg. Conclusion: SBP exhibits a U-shaped relationship with all-cause mortality in patients with AF, balancing against a monotonic increase in ischaemic stroke and intracranial haemorrhage at higher pressures. A pragmatic target SBP of 120–130 mmHg with DBP kept above ∼75–80 mmHg, appears to optimize the balance between stroke prevention, bleeding risk, and survival.


  • Open Access

    Cardiac resynchronization therapy with or without atrioventricular node ablation in atrial fibrillation: the CAAN-AF trial

    by Prashanthan Sanders, Jonathan P Ariyaratnam, Martin K Stiles, Alexis Puvrez, Stephen J Nicholls, Walter P Abhayaratna, Mark J Perrin, Jeff Alison, Rajeev K Pathak, Anand Ganesan, et al.

    Background and Aims: Patients with heart failure with reduced ejection fraction (HFrEF) derive less benefit from cardiac resynchronization therapy (CRT) if they have coexisting atrial fibrillation (AF). Observational data suggest that atrioventricular node ablation (AVNA) may enhance CRT efficacy in this population. This trial aimed to evaluate the effect of AVNA compared with medical rate control therapy (MRCT) on CRT outcomes in patients with HFrEF and permanent AF. Methods: The CAAN-AF trial was an international, prospective, multicentre, randomized controlled trial evaluating the impact of AVNA in patients with HFrEF, permanent AF, and CRT-defibrillators (CRT-D). Participants were randomly assigned (1:1) to AVNA or MRCT targeting a resting heart rate <90 bpm. All participants received device optimization. The primary endpoint was a composite of all-cause mortality and nonfatal heart failure events. Secondary endpoints included cardiovascular mortality, unplanned hospitalizations, ventricular arrhythmias requiring device therapy, 6-min walk distance (6MWD), and quality of life. Results: With early termination of the trial due to futility, a total of 143 patients were randomized (67 to AVNA, 76 to MRCT). Baseline characteristics were similar across groups. No significant difference was found in the primary endpoint [47 vs. 46 events; incident rate ratio (IRR), 1.16; 95% confidence interval (CI), 0.60–2.24]. Secondary outcomes, including cardiovascular mortality (odds ratio, 1.93; 95% CI 0.60–6.20), unplanned hospitalizations (IRR, 1.01; 95% CI 0.71–1.74), ventricular arrhythmias requiring device therapy (IRR, 0.68; 95% CI 0.17–2.63), 6MWD, and SF-36 scores, also showed no significant differences. Conclusions: This randomized trial of patients with permanent AF and CRT-D found no evidence of a reduction in all-cause mortality and nonfatal heart failure events with AVNA compared with MRCT. Trial Registration: NCT01522898.


  • Open Access

    Transseptal access with an electrified guidewire and large pulsed field ablation sheath

    by Sanjai Pattu Valappil, Emami Mehrdad, Alexis Puvrez, Domenico Barbaro, Alessandra Pina, Saikiran Kakarla, Jonathan P Ariyaratnam, Abhinav B Anand, Samuel J Tu, Neshi Weerasooriya, et al.

  • The impact of prolonged waiting list times for ablation of atrial fibrillation on arrhythmia recurrence after ablation

    by Jonathan P. Ariyaratnam, Gregory Horsfall, Scott A. Gall, Gavin S. Chu, Aruna V. Arujuna, Shajil Chalil